Tech Company Financing Transactions

Laverock Therapeutics Funding Round

Laverock Therapeutics closed a $16.5 million Seed financing round on 9/28/2023. Backers included Calculus Capital, Eli Lilly and Company and Eos Advisory.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Proceeds Purpose
The company intends to use the funds to further development of its GEiGS technology and progression of its programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumour responsive T-cell and macrophage based immune therapies, through to in vitro and in vivo validation. A key part of this next phase will be bringing on new members of the team and expanding lab facilities.

Company Information

Company Status
Private & Independent
Mailing Address
Incubator Building, Stevenage Bioscience Catalyst, Gunnels
Stevenage, SG1 2FX
Email Address
Laverock was founded around the core Gene Editing induced Gene Silencing Platform -- a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.
Laverock Therapeutics LinkedIn Company Profile
Social Media
Laverock Therapeutics Company Twitter Account
Company News
Laverock Therapeutics News
Laverock Therapeutics on Facebook
Laverock Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
David Venables
  David Venables LinkedIn Profile  David Venables Twitter Account  David Venables News  David Venables on Facebook
Chief Financial Officer
Sandy McDougall
  Sandy McDougall LinkedIn Profile  Sandy McDougall Twitter Account  Sandy McDougall News  Sandy McDougall on Facebook
Chief Operating Officer
Tom Payne
  Tom Payne LinkedIn Profile  Tom Payne Twitter Account  Tom Payne News  Tom Payne on Facebook
Chief Scientific Officer
Vlad Seitan
  Vlad  Seitan LinkedIn Profile  Vlad  Seitan Twitter Account  Vlad  Seitan News  Vlad  Seitan on Facebook
Chief Technical Officer
Tim Allsopp
  Tim Allsopp LinkedIn Profile  Tim Allsopp Twitter Account  Tim Allsopp News  Tim Allsopp on Facebook



Browse more venture capital transactions:

Prev: 9/28/2023: Triastek venture capital transaction
Next: 9/28/2023: Kamino Retail venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary